Virtu Financial LLC Buys New Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Virtu Financial LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,051 shares of the medical research company’s stock, valued at approximately $601,000.

Several other large investors also recently bought and sold shares of CRL. State Street Corp lifted its holdings in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Quest Partners LLC increased its position in Charles River Laboratories International by 135,175.0% during the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock worth $1,118,000 after buying an additional 5,407 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock valued at $22,060,000 after buying an additional 3,714 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Charles River Laboratories International by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after acquiring an additional 32,311 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after acquiring an additional 3,268 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of several research reports. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. Finally, Evercore ISI upped their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $214.00.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $190.46 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The firm has a market capitalization of $9.74 billion, a P/E ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38. The company’s fifty day moving average is $194.35 and its two-hundred day moving average is $203.02.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the firm earned $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. Analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).